Here's how the PD-(L)1xVEGF bispecific race is looking so far

The competitive landscape for PD-(L)1xVEGF bispecifics is finally taking shape. For the last couple years, much of the attention has focused on Summit Therapeutics and its lead drug ivonescimab. Now, two other challengers are revving ...